A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02937584
• Other study ID #: PT003019
• Status: Completed
• Phase: Phase 3
• Start date: December 29, 2016
• Est. completion date: May 28, 2018

Study information

• Verified date: June 2019
• Source: Pearl Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to severe chronic obstructive pulmonary disease (COPD) following chronic dosing after approximately two weeks treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: May 28, 2018
• Est. primary completion date: May 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or Child bearing potential, has a negative urine pregnancy test at Visit 1, and agrees to use acceptable contraceptive methods used consistently and correctly

• Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)

• Current or former smokers with a history of at least 10 pack-years of cigarette smoking.

• At Visit 1, FEV1/FVC ratio must be <0.70

• At Visit 1, post-bronchodilator FEV1must be >30% and <80% predicted normal value, calculated using The Third National Health and Nutrition Examination Survey (NHANES III) reference equations.

Exclusion criteria:

• Significant diseases other than COPD, i.e., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.

• Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.

• Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.

• Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).

• Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).

• Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated.

• Subjects who have a history of hypersensitivity to ß2-agonists, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI.

Related Conditions & MeSH terms

• COPD, Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• GP MDI (PT001) 14.4 µg
Glycopyrronium
• FF MDI (PT005) 9.6 µg
Formoterol Fumarate

Locations

Country	Name	City	State
Belgium	Research Site	Edegem
Belgium	Research Site	Erpent

Sponsors (1)

Lead Sponsor	Collaborator
Pearl Therapeutics, Inc.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Specific Image-Based Airway Volume (siVaw)	Specific image-based airway volume. Average across lobe, adjusted for lobe volume. Ratio to baseline	Baseline, Day 15
Primary	Specific Image-based Airway Resistance (siRaw)	Specific image-based airway resistance (siRaw). Average across lobes, adjusted for lobe volume. Ratio to baseline.	Baseline, Day 15
Secondary	Image-based Airway Volume (iVaw)	Image-based airway volume (iVaw) without correction for lobe volume. Ratio to baseline.	Baseline, Day 15
Secondary	Image-based Airway Resistance (iRaw)	Image-based airway resistance (iRaw) without correction for lobe volume. Ratio to baseline.	Baseline, Day 15
Secondary	FEV1	FEV1 Change from baseline in Forced Expiratory Volume at 1 second.	Baseline, Day 15
Secondary	Functional Residual Capacity (FRC)	Functional residual capacity (FRC). Ratio to baseline.	Baseline, Day 15

External Links

•   Link
•   Link